Hepatitis C Inhibitors Targeting Viral Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C, primarily relying on interferon and ribavirin, are lengthy, have insufficient cure rates for certain genotypes, and are associated with significant side effects, leading to treatment discontinuation and relapse issues.
Innovation Solution
Development of compounds of formula (I) and their pharmaceutical compositions that inhibit hepatitis C virus replication, offering alternative treatment options potentially with reduced side effects and improved efficacy across various genotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon and ribavirin combination therapy is used to treat hepatitis C, then viral suppression is achieved, but treatment duration becomes excessively long (24-48 weeks) and cure rates remain insufficient for certain genotypes
Solution Approach 1:
The patent applies parameter changes by developing novel compounds with modified chemical structures (formula I and II) that target HCV replication differently from existing therapies. These compounds represent a fundamental change in the therapeutic parameter of viral inhibition mechanism, enabling shorter treatment durations and improved cure rates across multiple genotypes including genotype 1
2Reliability
If interferon and ribavirin combination therapy is used to treat hepatitis C, then viral replication is inhibited, but significant side effects occur leading to treatment discontinuation and relapse
Solution Approach 1:
The patent extracts the essential therapeutic function of viral replication inhibition while eliminating the harmful side effects associated with interferon and ribavirin. The novel compounds of formula (I) and (II) achieve HCV suppression through a different mechanism that does not produce the flu-like symptoms, anemia, and other adverse effects of conventional therapy
Solution Approach 2:
The patent introduces intermediary compounds with novel chemical structures that mediate viral inhibition through alternative pathways. These compounds serve as intermediaries between the host immune system and HCV, providing viral suppression without the direct immunomodulatory side effects of interferon
3Reliability
If standard interferon and ribavirin therapy is administered, then some viral response is achieved, but patient compliance deteriorates due to treatment length and side effects
Solution Approach 1:
The patent applies preliminary action by developing compounds that achieve viral suppression more rapidly and sustain longer responses. The novel compounds of formula (I) and (II) are designed to establish effective viral inhibition earlier in treatment and maintain it with shorter overall treatment duration, thereby improving compliance before patients experience fatigue from prolonged therapy
Data Source
AI summary
This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.